Metropolis Healthcare Ltd. (METROPOLIS) AI Stock Analysis

• Market Cap: ₹107.86B
• Dividend Yield: 0.71%
• Average Volume (3M): 3.18K
• Price to Earnings (P/E): 69.4
• Beta (1Y): 0.72
• Revenue Growth: 12.86%
• EPS Growth: 10.42%
• Country: IN
• Employees: 4,313
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 8.70
• Shares Outstanding: 51,807,460
• 10 Day Avg. Volume: 3,842
• 30 Day Avg. Volume: 3,183
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,275.00
• Price Target Upside: 12.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 62 Neutral
• Price Target: ₹2,150.00 ▲(5.99% Upside)

Metropolis Healthcare Ltd. demonstrates strong financial performance with robust revenue and profit growth, a solid balance sheet, and efficient cash flow management. However, technical indicators suggest a bearish trend, and the high P/E ratio indicates overvaluation, which tempers the overall score.

Metropolis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, confirmation, and/or monitoring of the disease. The company also offers corporate wellness and hospital laboratory solutions, as well as clinical research services. As of March 31, 2022, it operated 171 clinical laboratories, 9,000 pick-up points, and 704 assisted referral centers. The company was founded in 1980 and is headquartered in Mumbai, India.

How the Company Makes Money

Metropolis Healthcare Ltd. generates revenue primarily through its extensive network of diagnostic laboratories and patient service centers. The company's main revenue streams include fees charged for various clinical laboratory tests and pathology services. These tests cover a broad spectrum, from routine blood tests and imaging to specialized diagnostics, catering to both walk-in patients and institutional clients such as hospitals and clinics. Additional revenue is derived from preventive healthcare packages and wellness programs aimed at promoting early detection and prevention of diseases. Furthermore, Metropolis may engage in partnerships with healthcare providers, insurance companies, and corporate clients to offer customized health check-up plans, which contribute to its earnings. The company invests in technological advancements and quality assurance to maintain its competitive edge and ensure customer satisfaction, which is crucial for sustaining its revenue growth.

Metropolis Healthcare Ltd. Financial Statement Overview

Summary

Metropolis Healthcare Ltd. exhibits strong financial health across all verticals. Income statement shows robust revenue and profit growth with impressive margins. Balance sheet is solid with low leverage and strong equity base, reducing financial risk. Cash flow is efficient, supporting expansion and shareholder value.

Income Statement

Metropolis Healthcare Ltd. shows strong performance with a consistent increase in revenue and profitability. The gross profit margin is impressive at 79.8% for 2025, indicating effective cost management. The net profit margin has also improved, reaching 10.9% in 2025, reflecting enhanced operational efficiency. EBIT and EBITDA margins stand at 55.5% and 22.8% respectively, demonstrating robust profitability. Revenue growth of 10.2% from 2024 to 2025 further underscores the company's solid market position and growth potential.

Balance Sheet

The balance sheet of Metropolis Healthcare Ltd. is strong, supported by a healthy equity ratio of 71.3% in 2025, indicating a solid capital structure. The debt-to-equity ratio is manageable at 0.15, reflecting low leverage and thus reduced financial risk. Return on equity is 10.9%, highlighting efficient use of shareholder funds. Overall, the company maintains a stable and low-risk financial position, which provides a strong foundation for future growth.

Cash Flow

Cash flow generation is robust, with a free cash flow growth rate of 9.5% from 2024 to 2025, indicating efficient operations and sound financial health. The operating cash flow to net income ratio is strong at 1.81, showing that the company generates ample cash relative to its profitability. Free cash flow to net income ratio is high at 1.51, demonstrating a solid ability to convert profits into cash. Overall, Metropolis Healthcare Ltd. showcases a strong cash flow profile, facilitating business expansion and shareholder returns.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.31B	13.31B	11.48B	12.08B	12.28B	9.98B
Gross Profit	8.52B	10.63B	8.88B	5.81B	9.41B	7.38B
EBITDA	3.10B	3.03B	3.08B	2.97B	3.81B	3.01B
Net Income	1.45B	1.45B	1.43B	1.28B	2.14B	1.83B
Balance Sheet
Total Assets	18.67B	18.67B	15.02B	15.55B	15.30B	10.04B
Cash, Cash Equivalents and Short-Term Investments	1.18B	1.18B	1.20B	1.24B	1.81B	4.20B
Total Debt	2.04B	2.04B	2.66B	1.97B	3.79B	1.12B
Total Liabilities	5.33B	5.33B	5.11B	4.56B	6.42B	2.96B
Stockholders Equity	13.31B	13.31B	9.88B	10.96B	8.86B	7.07B
Cash Flow
Free Cash Flow	0.00	2.19B	1.94B	2.00B	2.23B	2.21B
Operating Cash Flow	0.00	2.63B	2.47B	2.64B	2.53B	2.49B
Investing Cash Flow	0.00	-2.01B	467.94M	-894.12M	-7.38B	617.01M
Financing Cash Flow	0.00	-866.34M	-2.92B	-1.81B	1.63B	-326.90M

Metropolis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2028.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Positive. The current price of 2028.5 is below the 20-day moving average (MA) of 2126.14, below the 50-day MA of 2076.09, and above the 200-day MA of 1846.46, indicating a neutral trend. The MACD of -5.95 indicates Positive momentum. The RSI at 48.25 is Neutral, neither overbought nor oversold. The STOCH value of 74.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:METROPOLIS.

Metropolis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LALPATHLAB	70 Outperform	276.76B	53.65	22.42%	0.74%	10.57%	34.11%
THYROCARE	69 Neutral	63.88B	60.02	16.74%	1.75%	21.82%	36.97%
VIJAYA	67 Neutral	108.14B	71.98	17.98%	0.19%	22.34%	20.71%
KRSNAA	63 Neutral	27.44B	34.06	8.79%	0.34%	13.78%	32.21%
METROPOLIS	62 Neutral	₹107.86B	69.41	―	0.71%	12.86%	10.42%
HCG	61 Neutral	90.65B	246.26	4.81%	―	16.85%	-29.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%